Showing results (1-10 of 173) with videos related to
Sort By:
Pageof 18
Cancer Research|October 17, 2022
A Detouring Experience Not Recommended: Lessons Learned from PF00299804Molly Li, Kevin Mok, Tony MokAnti-Cancer Drugs|June 6, 2008
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of lifeHatem A Azim, Tony MokDiscovery Medicine|December 31, 2009
A small step towards personalized medicine for non-small cell lung cancerTony Mok, Yi-Long Wu, Li ZhangCancer|September 3, 2015
Novel targeted agents for the treatment of lung cancer in ChinaSi-Yang Liu, Tony Mok, Yi-Long WuJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?Tony Mok, Jin-Ji Yang, Kwok-Chi LamFuture Oncology (London, England)|May 7, 2014
Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancerTony Mok, Kirsty Lee, Michael Tang, et al.Cancer Treatment Reviews|June 19, 2012
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)Corey J Langer, Tony Mok, Pieter E PostmusAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small MoleculeJordi Rodon Ahnert, Nathanael Gray, Tony Mok, et al.Cancer Discovery|April 3, 2021
The Promising Evolution of Targeted Therapeutic Strategies in CancerSolange Peters, Tony Mok, Antonio Passaro, et al.Nature Cancer|February 5, 2022
Overcoming therapy resistance in EGFR-mutant lung cancerAntonio Passaro, Pasi A Jänne, Tony Mok, et al.Pageof 18